do glp 1 agonists cause pancreatic cancer GLP-1–Based Therapies: The Dilemma of Uncertainty Ozempic and Cancer Risk: Study

Yuan Y, Yan Z, Lao Q, Jiang N, Wu S, Lu Q, et al

GLP-1 side effects and safety considerations As with any medication, you need to be aware of the potential side effects when taking a GLP-1

Calorie restriction decreases murine and human pancreatic tumor cell growth, nuclear factor-B activation, and inflammation-related gene expression in an insulin-like growth factor-1-dependent manner

Final Thoughts Retatrutide has emerged as one of the most exciting developments in the peptide industry

Cardiovascular data on endpoints like MACE-3 or MACE-4 are presently not available yet, but an early meta-analysis demonstrated at least cardiovascular safety in patients with T2D treated with tirzepatide (78, 79)

On average, volunteers in the retatrutide clinical trial who received the study drug rather than a placebo lost an average of 70.3 pounds over about a year-and-a-half, with more than 45% of participants losing more than 30% of their body weight